The glycogen storage diseases are disorders of glycogen metabolism in which an excessive amount of glycogen accumulates in several tissues. The presence of an excessive amount of glycogen may physically interfere with the function of the tissue but many of the clinical features of the various types of glycogen storage diseases are due directly or indirectly to the impairment of carbohydrate metabolism.
Claude Bernard first isolated glycogen from the liver in 1857 and described its chemical and physiological properties. A little over 70 years later, two forms of glycogen storage disease were recognized: in one form, glycogen was present in large amounts in almost all the tissues of the body, including the heart and tongue, while in the other the excess of glycogen was restricted to the liver and kidney. In spite of much ingenious speculation, no headway was made in the understanding of these disorders until 1952 when Cori and Cori demonstrated the absence of the enzyme glucose 6-phosphatase in the liver of children suffering from the hepatorenal type of glycogen storage disease. Since then, at least five other types of glycogen storage disease have been reliably recognized and classified on the basis of specific enzyme defects related to glycogen metabolism (Table I) .
THE GLYCOGEN MOLECULE
The glycogen molecule is composed of over 120,000 glucosyl units linked together in such a way that it assumes a tree-like appearance with relatively long inner chains, consisting of up to 20 glucosyl moieties, and shorter outer chains of eight to 12 glucosyl groups branching off from the inner chains ( Fig. 1) . The glycogen molecule is large enough to be visualized under the electron microscope: it is roughly spherical in shape with a molecular weight of 20 x 106 and a volume of 200 cubic Angstroms but, depending upon the nutritional state, it may aggregate with other glycogen molecules into even larger particles. Glycogen particles are usually present in the cytoplasm, but they also occur in the lysosomes, and in certain pathological conditions may be seen in the nucleus and the mitochondria.
GLYCOGEN SYNTHESIS AND DEGRADATION
These occur by different pathways. The initial step is the conversion of glucose by hexokinase to glucose 6-phosphate, which is then re-arranged to form glucose 1-phosphate. The first ILE I Glycogen storage diseases step of glycogen synthesis proper is the formation of uridine diphosphoglucose (UDPG) from glucose 1-phosphate. This reaction is reversible, but the next step is the irreversible reaction of UDPG with 'glycogen synthetase', which results in the formation of a chain in which glucose molecules are joined to one another in a 1: 4-linkage (Fig. 1) . This reaction is stimulated by glucose 6-phosphate and by insulin. When the chains reach a length of about 12 glucosyl units, three or four of the units are transferred from the end of that chain to another chain but there they are attached in a 1: 6-linkage in such a way that a branch point is formed (Fig. 1) . The sequential interactions of 'glycogen synthetase' and 'branching enzymes' result in the typical branched glycogen molecule which has a characteristic colour and light absorption at 460 m,u when stained with iodine.
Glycogen breakdown is initiated by phosphorylase, which successively hydrolyzes all the 1: 4-linkages in a chain, each time producing glucose I -phosphate, but is incapable of splitting the 1: 6-links at branch points. To break through the 1: 6 link another enzyme is required, the 'debranching enzyme', which yields a molecule of glucose and through its action exposes another chain of 1: 4-linked glucosyl units to the action of phosphorylase. Thus the degradation of glycogen, like its synthesis, requires the sequential interaction of two distinct enzymes and results in the formation of glucose and of glucose 1-phosphate which can be used by the cells for their metabolic requirements. Not all the glycogen is broken down by this mechanism: some of it finds its way into the intracellular lysosomes where it is hydrolysed by a-glucosidases to form maltose and glucose.
The identity and quantitative importance in human metabolism of the separate pathways of glycogen synthesis and degradation were only clarified when the specific enzyme defects of the glycogen storage diseases were recognized. Their study emphasizes the contribution which clinical medicine can make to basic biochemistry and the help which can be gained from an understanding of the biochemical processes in the management of patients suffering from metabolic disorders. A measure of the wide interest which their study has aroused is the number of reviews of this subject which have appeared recently (Steinitz, 1967; Brown and Brown, 1968; Hers and van Hoof, 1968;  Symposium, Amer J. clin Path., 1968; Mahler, 1969 The accumulation of abnormal amounts of glycogen in this disease is confined to the liver, kidney, and intestinal mucosa, ie, tissues which normally show glucose 6-phosphatase activity. Although all these tissues can also metabolize glycogen by other pathways, it would seem that the enzyme is of importance in the control of their glycogen content. In other tissues, such as muscle, which normally possess no glucose 6-phosphatase, there is no excess of glycogen.
Absence of enzyme activity in this disorder has been shown by direct assay of the enzyme in biopsies
_ ,-9-11 -P g-6-P X (Table  II) . Glucose 6-phosphatase is the enzyme which controls the final common pathway for the release of glucose as the result of glycogenolysis and gluconeogenesis in the liver. In the absence of the enzyme stimulation of these processes cannot result in a rise of the blood glucose level, but the production of lactic acid proceeds freely (Fig. 2) .
Glucagon Normally the intramuscular administration of 0 5 mg glucagon, which accelerates glycogen breakdown, causes the blood glucose concentration to increase within 15 to 30 minutes, with only a slight increase in the concentration of lactic acid. In the absence of the enzyme there is no rise in the blood glucose level but a considerable Intravenous infusion ofgalactose orfructose These two sugars are converted in the liver through a series of enzymatic reactions to glucose 6-phosphate and would then normally be dephosphorylated to glucose and raise the blood glucose level. In the absence of glucose 6-phosphatase there is no increase in blood glucose, but the lactic acid concentration in the blood increases as the result of the metabolism of glucose 6-phosphate through the glycolytic pathway.
The failure of the blood glucose level to rise and the abnormal rise in blood lactate after these two tests differentiates type I from all the other established types of glycogen storage disease.
SPECIFIC INVESTIGATIONS Final proof of the diagnosis, however, must rest on the demonstration of a glycogen content more than 4% of wet weight and a very low glucose 6-phosphatase activity in a sample of liver obtained by open or needle biopsy.
Estimation of glucose 6-phosphatase activity in intestinal biopsy material is an acceptable alternative to liver biopsy and is the preferred technique for the investigation of relatives of affected patients, levels Although this was one of the earlier types of glycogen storage disease to be recognized as a clinical entity (Pompe, 1932) , it is one of the most recent in which a specific enzyme defect has been demonstrated (Hers, 1963) . In this disease all the tissues of the body contain large amounts of glycogen which may be sufficient to interfere mechanically with the contractility of the heart muscle and to cause death from heart failure. On the other hand general disturbances of carbohydrate and lipid metabolism are only remarkable by their absence (Fig. 3) . FIG. 3. Type II glycogen storage disease. Glycogen accumulates within lysosomes (heavily outlined) due to absence of 'acid maltase' (X).
In normal cells lysosomes contain a variety of hydrolytic enzymes active at a low pH, which degrade macromolecular compounds such as glycogen, proteins, and lipids which have been engulfed by these organelles (De Duve, 1959) . In type II glycogenosis Hers demonstrated the absence of an ac-: 4-glucosidase, which normally splits any glycogen enclosed within the lysosome into maltose and glucose. In the absence of the enzyme glycogen accumulates in increasing amounts and with the electron microscope a large aggregation can be seen surrounded by the lysosomal membrane. The structure of the glycogen molecule isolated from the tissues is normal.
It was shown experimentally (Cuthbertson and Fleming, 1964 ) that a glucosidase derived from Aspergillus niger was capable of lowering liver, 3 muscle, and heart glycogen in the rat after intraperitoneal administration. Baudhuin, Hers, and Loeb (1964) The diagnosis is confirmed by demonstrating the absence of x-l,4-glucosidase in liver or in leucocytes using a biochemical assay devised by Hers (1963) . In heterozygous carriers the leucocyte enzyme is reduced.
TYPE III (,LYCOGEN STORAGE DISEASE ('DEBRANCHING ENZYME DEFICIENCY) This disease is characterized by the absence of the 'debranching enzyme', amylo-l: 6-glucosidase, and an accumulation of a dextrin-like glycogen with abnormally short outer chains. In the absence of the debranching enzyme, phosphorylase acts on successive 1: 4-glucosyl linkages in the outer chains of the glycogen molecule, but reaches the limit of its action close to a 1: 6-linked branch point, leaving polysaccharide whose structure resembles that of a pollarded tree and is described as a 'limit dextrin' (Fig. 4) FUNCTIONAL TESTS These are summarized in Figure   5 .
Glucagon In a fasting patient the outer chains of the glycogen molecule have already been 'cropped' as far as a branch point by phosphorylase, so that further stimulation of phosphorylase activity by glucagon remains ineffective and there is no rise in the blood glucose level. After a meal, however, the outer 1: 4-linked chains lengthen and now provide a substrate on which phosphorylase can act, so that an injection of glucagon under these conditions can produce an increase in the blood glucose level.
Infusions of galactose or fructose These result in a normal rise in the blood glucose level because there is no interference with the conversion to glucose of the glucose 6-phosphate, which is formed from these sugars in the liver. There is no abnormal increase in blood lactate.
SPECIFIC INVESTIGATIONS Glycogen isolated from tissues or red blood cells can be shown to possess short outer chains of 1,4-linked glucosyl units. When stained with iodine, the limit dextrin has a light-absorption maximum at 460 m,u.
The diagnosis is confirmed by carrying out an assay for the debranching enzyme, for which an elegant technique has recently been developed depending upon the release of 14C-glucose from labelled glycogen (Hers and van Hoof, 1968) .
Heterozygous carriers of the disease can be detected by assay of amylo-1, 6-glucosidase activity in leucocytes or erythrocytes, in which the activity is about 50 % of normal.
TYPE IV GLYCOGEN STORAGE DISEASE ('BRANCHING ENZYME' DEFICIENCY)
Type IV glycogen storage disease is caused by a deficiency of the 'branching enzyme', oc-1,4-glucan--* 1,6-transglucosidase, and is characterized by the accumulation of a glycogen with abnormally long outer chains. The outer chains lengthen beyond the normal 8 to 10 glucosyl units, because units continue to be joined in 1,4-linkages through the action of 'glycogen synthetase' without the formation of branch points (Fig. 5) . The accumulation of this material in the liver is associated with the development of cirrhosis, progressing to portal hypertension and hepatic failure early in life.
It appears to be a rare form of glycogen storage and so far only six cases have been described in the literature (Andersen, 1952; Sidbury, Mason, Bums, and Ruebner, 1962; Brown and Brown, 1966; Holleman, van der Haar, and de Vaan, 1966; Fernandes and Huijing, 1968; Levin, Burgess, and Mortimer, 1968) . The clinical features of the disease are predominantly those of portal hypertension and cirrhosis. Deposits of the abnormal glycogen occur also in several other tissues, including the spinal cord, and in leucocytes and erythrocytes.
The structure of the glycogen in this disease resembles that of starch and, like starch, it is relatively insoluble in water and stains blue with iodine. The disease is therefore sometimes called 'amylopectinosis'.
All the patients described have died early in life with a cirrhotic liver. An attempt has been made to prevent the development of cirrhosis by treatment with steroids (Sidbury et al, 1962) . More recently in another patient liver glycogen was reduced by the intramuscular administration of a purified fungal oa-glucosidase (Fernandes and Huijing, 1968) , but in this case cirrhosis was already far advanced before treatment with the enzyme was begun.
Diagnostic tests are summarized in Table II (Rowland, Araki, and Carmel, 1965) and the most recent studies by McArdle and his colleagues (Gruener, McArdle, Ryman, and Weller, 1968) indicate that the contractures may be due to a partial failure by the sarcoplasmic reticulum to reaccumulate calcium during vigorous exercise. 'Blebs' of glycogen are present just internal to the sarcolemma and electron microscopy shows accumulation of glycogen within distorted mitochondria (Gruener et al, 1968) .
Phosphorylase activity is the final expression of the integrated action on the enzyme of several activating and inactivating processes (Sutherland and Robison, 1966) (Robbins, 1960) ; the only other type of glycogen storage disease in which absence of the specific enzyme protein has been demonstrated in this way is that due to phosphofructokinase deficiency but it is reasonable to assume, though not proven, that in the other types of glycogen storage disease the specific enzyme protein is also absent.
BLOOD CHEMISTRY At rest, there is no abnormality of carbohydrate or lipid metabolism.
FUNCTIONAL TESTS After exercise, and especially if it has been performed under relatively ischaemic conditions, there is a complete absence of a rise of lactic acid concentration in venous blood draining the ischaemic muscle (Fig. 6) . After the exercise the extraction of glucose and fatty acids from blood flowing through the exercised muscles is greatly increased.
Glucagon The blood glucose concentration rises in a normal manner after the injection of glucagon because it stimulates liver phosphorylase, which is immunologically distinct from the muscle enzyme (Henion and Sutherland, 1957) and therefore may be presumed to be under separate genetic control.
There is a normal rise in the blood glucose concentration after an intravenous infusion of fructose or galactose.
SPECIFIC TESTS Muscle biopsies contain a moderate excess of glycogen of normal structure. Phosphorylase assay in muscle shows that there is no enzyme activity, even after the addition of adenosine 5-monophosphate which activates the inactive form of phosphorylase. No (Sokal, Lowe, Sarcione, Mosovich, and Doray, 1961) or glycogen synthetase deficiency (Parr, Teree, and Lamer, 1965 In a multienzyme system such as that concerned with carbohydrate metabolism it is not surprising that several other metabolic blocks should have been discovered associated with an abnormal accumulation of glycogen.
The two diseases which are convincingly documented are phosphofructokinase deficiency (Tarui, Okuno, Ikura, Tanaka, Suda, and Nishikawa, 1965; Layzer, Rowland, and Ranney, 1967) and phosphoglucomutase deficiency (Illingworth and Brown, 1964) .
PHOSPHOFRUCTOKINASE DEFICIENCY
The clinical manifestations of this disease are similar to those of type V glycogenosis and are presumably the result of diminished energy production due to interference with the normal glycolytic pathway (Fig. 8) . This is one of the few inherited metabolic diseases in which absence of the enzyme protein has been demonstrated by the use of an antiserum to the enzyme (Layzer et al, 1967) .
Blood chemistry There is no abnormality at rest.
Response to glucagon There is no interference with glucose production by the liver and therefore there is a normal hyperglycaemic response after an injection of glucagon.
Galactose infusion results in a normal rise of blood glucose level.
Ischaemic forearm exercise Glycolysis cannot proceed beyond fructose 1-phosphate, therefore no lactate is formed when ischaemic exercise is undertaken.
Special (Illingworth and Brown, 1964 (Stanbury, Wyngaarden, and Fredrickson, 1966 The glycogen storage diseases, like other inherited metabolic diseases, may be natural experiments in evolution and, because they upset the usual complex self-regulatory mechanisms of the cell, they present a unique opportunity for studying intracellular biochemical processes.
